Efficacy and Safety of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion Administered as Monotherapy in Patients with Parkinson's Disease

被引：0
|
作者：
Aldred, J.
Henriksen, T.
Bouchard, M.
Martinez-Castrillo, J.
Soileau, M.
Spiegel, A.
Bergmann, L.
Gupta, R.
Kukreja, P.
Standaert, D.
机构：
来源：
MOVEMENT DISORDERS | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
19
引用
收藏
页码：S7 / S8
页数：2
相关论文
共 50 条
  • [21] Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial
    Soileau, Michael J.
    Aldred, Jason
    Budur, Kumar
    Fisseha, Nahome
    Fung, Victor Sc
    Jeong, Anna
    Kimber, Thomas E.
    Klos, Kevin
    Litvan, Irene
    O'Neill, Daniel
    Robieson, Weining Z.
    Spindler, Meredith A.
    Standaert, David G.
    Talapala, Saritha
    Vaou, Eleni Okeanis
    Zheng, Hui
    Facheris, Maurizio F.
    Hauser, Robert A.
    LANCET NEUROLOGY, 2022, 21 (12) : 1099 - 1109
  • [22] Efficacy and Safety of Foslevodopa/Foscarbidopa in People with Parkinson's disease (PD) with and Without Care Partner Support
    Soileau, M.
    Bronstein, J.
    Harmer, L.
    Shah, M.
    Gupta, R.
    Metman, L. Verhagen
    MOVEMENT DISORDERS, 2024, 39 : S313 - S315
  • [23] Levodopa Pharmacokinetics in Switching From Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson's Disease: A Case Report
    Nukariya, Tomonori
    Tezuka, Toshiki
    Okusa, Shohei
    Okochi, Ryotaro
    Sakai, Yuto
    Nihei, Yoshihiro
    Nakahara, Jin
    Seki, Morinobu
    JOURNAL OF MOVEMENT DISORDERS, 2025,
  • [24] Continuous Subcutaneous Foslevodopa-Foscarbidopa in Parkinson's Disease: A Mini-Review of Current Scope and Future Outlook
    Aubignat, Mickael
    Tir, Melissa
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2024, 11 (10): : 1188 - 1194
  • [25] Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Results by Age, Disease Duration, and Baseline "Off" Time
    Isaacson, S.
    Di Lorenzo, G.
    Facheris, M.
    Fung, V.
    Henriksen, T.
    Ikenaka, K.
    Jia, J.
    Kern, D.
    Kukreja, P.
    Santos Garcia, D.
    Spiegel, A.
    Zhang, Z.
    Bergmann, L.
    Carroll, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 444 - 445
  • [26] Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease
    Brohee, Sacha
    Roze, Emmanuel
    Grabli, David
    Letrillart, Helene
    Mantisi, Lise
    Foucard, Cendrine
    Hainque, Elodie
    Cormier, Florence
    Meneret, Aurelie
    Hauw, Fabien
    MOVEMENT DISORDERS CLINICAL PRACTICE, 2025,
  • [27] Stability and Predictability of Motor Symptom Control in Patients with Advanced Parkinson's Disease (aPD) Receiving Continuous Subcutaneous Foslevodopa/Foscarbidopa (LDP/CDP)
    Pahwa, R.
    Malaty, I.
    Soileau, M.
    Fung, V.
    Garcia, D. Santos
    Carroll, C.
    Henriksen, T.
    Epstein, A.
    Yan, C.
    Alobaidi, A.
    Shewale, A.
    Spiegel, A.
    Facheris, M.
    Shah, M.
    Kukreja, P.
    Zamudio, J.
    Chaudhuri, K.
    MOVEMENT DISORDERS, 2023, 38 : S44 - S45
  • [28] Improvement in Motor Symptoms and Quality of Life in Patients with an Earlier Stage of Advanced Parkinson's Disease Treated with Foslevodopa/Foscarbidopa Subcutaneous 24 Hour Infusion
    Antonini, A.
    Bergmans, B.
    Kern, D.
    Odin, P.
    Bergmann, L.
    Gupta, R.
    Homola, J.
    Shah, M.
    Zamudio, J.
    Standaert, D.
    MOVEMENT DISORDERS, 2023, 38 : S10 - S10
  • [29] Potential Psychosis Induced by a Sustained High Plasma Levodopa Concentration Due to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson's Disease: A Case Report
    Tezuka, Toshiki
    Nukariya, Tomonori
    Kizuka, Yuta
    Okusa, Shohei
    Okochi, Ryotaro
    Sakai, Yuto
    Nihei, Yoshihiro
    Nakahara, Jin
    Seki, Morinobu
    JOURNAL OF MOVEMENT DISORDERS, 2024, 17 (04) : 453 - 455
  • [30] Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study
    Aldred, Jason
    Freire-Alvarez, Eric
    Amelin, Alexander V.
    Antonini, Angelo
    Bergmans, Bruno
    Bergquist, Filip
    Bouchard, Manon
    Budur, Kumar
    Carroll, Camille
    Chaudhuri, K. Ray
    Criswell, Susan R.
    Danielsen, Erik H.
    Gandor, Florin
    Jia, Jia
    Kimber, Thomas E.
    Mochizuki, Hideki
    Robieson, Weining Z.
    Spiegel, Amy M.
    Standaert, David G.
    Talapala, Saritha
    Facheris, Maurizio F.
    Fung, Victor S. C.
    NEUROLOGY AND THERAPY, 2023, 12 (06) : 1937 - 1958
12345